Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSL | P07711 | 7/20 | 0.39 |
| ▸ | CTSS | P25774 | 7/20 | 0.39 |
| ▸ | CTSK | P43235 | 5/20 | 0.39 |
| ▸ | MMP2 | P08253 | 1/20 | 0.38 |
| ▸ | MMP14 | P50281 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | USP30 | Q70CQ3 | 4/20 | 0.37 |
| ▸ | PLAU | P00749 | 1/20 | 0.37 |
| ▸ | HPN | P05981 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6705838 | 0.81 | CTSS (0.43) | CTSLCTSSCTSKPOLB | |
| SCHEMBL4795913 | 0.81 | CTSS (0.38) | CTSLCTSSCTSK | |
| SCHEMBL4799975 | 0.79 | CTSL (0.43) | CTSLCTSSCTSKUSP30PLAU | |
| SCHEMBL4802535 | 0.78 | CA2 (0.43) | POLBKMT2A | |
| SCHEMBL4796601 | 0.73 | CTSS (0.47) | CTSLCTSSCTSKUSP30PLAU | |
| SCHEMBL4797850 | 0.72 | MME (0.36) | CTSLCTSSCTSKMMP2KMT2A | |
| SCHEMBL4801077 | 0.72 | EPHX2 (0.47) | CTSLCTSSCTSKPOLB | |
| SCHEMBL3014755 | 0.72 | EPHX2 (0.47) | CTSLCTSSCTSKPOLB | |
| SCHEMBL4798052 | 0.72 | CTSS (0.38) | CTSLCTSSCTSKPOLB | |
| SCHEMBL4795302 | 0.71 | LMNA (0.48) | KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080242671-A1 | INHIBITORS OF CATHEPSIN S | IRM LLC (BM) | 2008-10-02 | — | — | US | claimed |
| US-20080242671-A1 | INHIBITORS OF CATHEPSIN S | IRM LLC (BM) | 2008-10-02 | — | — | US | disclosed |
| US-7384970-B2 | Inhibitors of cathepsin S | IRM LLC (BM) | 2008-06-10 | — | — | US | disclosed |
| US-20040248887-A1 | Inhibitors of cathepsin S | IRM LLC (BM) | 2004-12-09 | — | — | US | disclosed |
| WO-2004084843-A2 | INHIBITORS OF CATHEPSIN S | IRM LLC (BM) | 2004-10-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040248887-A1 | Inhibitors of cathepsin S | CTSS, CTSB, CTSZ | CTSL 11/4885CTSS 1/4885CTSK 9/4885 |
| US-20080242671-A1 | INHIBITORS OF CATHEPSIN S | CTSS, CTSB, CTSZ | CTSL 11/4885CTSS 1/4885CTSK 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.